Abstract |
Glaucoma is the major cause of irreversible blindness throughout the world. Of all of the treatments that are available at present, the most effective appears to be surgery; however, excessive conjunctival scarring can lead to surgical failure. In the last decade, the introduction of the anti-metabolites mitomycin-C and 5-fluorouracil as anti- scarring treatments have greatly improved the results of glaucoma surgery, but these agents are associated with complications that can potentially result in blindness. A possible target for a more physiological approach to anti- scarring is transforming growth factor beta. This review examines the role of transforming growth factor beta in conjunctival scarring and discusses promising new ways of modifying its activity.
|
Authors | M Francesca Cordeiro |
Journal | Clinical science (London, England : 1979)
(Clin Sci (Lond))
Vol. 104
Issue 2
Pg. 181-7
(Feb 2003)
ISSN: 0143-5221 [Print] England |
PMID | 12546640
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Transforming Growth Factor beta
|
Topics |
- Animals
- Cicatrix
(physiopathology)
- Conjunctival Diseases
(physiopathology)
- Filtering Surgery
(adverse effects)
- Glaucoma
(surgery)
- Humans
- Mice
- Transforming Growth Factor beta
(antagonists & inhibitors, physiology)
- Wound Healing
|